NI201400104A - Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento - Google Patents

Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento

Info

Publication number
NI201400104A
NI201400104A NI201400104A NI201400104A NI201400104A NI 201400104 A NI201400104 A NI 201400104A NI 201400104 A NI201400104 A NI 201400104A NI 201400104 A NI201400104 A NI 201400104A NI 201400104 A NI201400104 A NI 201400104A
Authority
NI
Nicaragua
Prior art keywords
treatment
esketamine
resistant
depression
refractory
Prior art date
Application number
NI201400104A
Other languages
English (en)
Inventor
Singh Jaskaran
Ivo Caers Lodewijk
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NI201400104A publication Critical patent/NI201400104A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se dirige a métodos para el tratamiento de la depresión refractaria al tratamiento o depresión resistente al tratamiento; los métodos comprenden administrar a un paciente que lo necesita una cantidad terapéuticamente eficaz de esketamina como monoterapia o como terapia de combinación con al menos un antidepresivo.
NI201400104A 2012-03-12 2014-09-10 Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento NI201400104A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261609641P 2012-03-12 2012-03-12
US201261610058P 2012-03-13 2012-03-13

Publications (1)

Publication Number Publication Date
NI201400104A true NI201400104A (es) 2016-11-30

Family

ID=47913632

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201400104A NI201400104A (es) 2012-03-12 2014-09-10 Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento

Country Status (14)

Country Link
US (2) US20130236573A1 (es)
KR (1) KR20140136982A (es)
CN (1) CN104519878A (es)
CL (1) CL2014002406A1 (es)
CO (1) CO7071129A2 (es)
CR (1) CR20140410A (es)
GT (1) GT201400191A (es)
HK (1) HK1209323A1 (es)
MX (1) MX2014010939A (es)
NI (1) NI201400104A (es)
PE (1) PE20141906A1 (es)
PH (1) PH12014501997A1 (es)
SG (1) SG11201405530SA (es)
WO (1) WO2013138322A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
US10583138B2 (en) 2012-07-12 2020-03-10 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
AU2014240102A1 (en) 2013-03-15 2015-09-17 Janssen Pharmaceutica Nv Pharmaceutical composition of S-ketamine hydrochloride
WO2014169272A1 (en) * 2013-04-12 2014-10-16 Icahn School Of Medicine At Mount Sinai Method for treating post-traumatic stress disorder
HUE056378T2 (hu) 2013-09-13 2022-02-28 Univ Chiba Nat Univ Corp R-Ketamin és sójának alkalmazása gyógyszerekként
EP3094312B1 (en) * 2014-01-14 2019-03-13 Children's Hospital Medical Center Compositions comprising ketamine for treating an autism spectrum disorder
WO2015171770A1 (en) * 2014-05-06 2015-11-12 Northwestern University Combinations of nmdar modulating compounds
WO2016025581A1 (en) 2014-08-13 2016-02-18 Janssen Pharmaceutica Nv Method for the treatment of depression
US20160074340A1 (en) * 2014-09-15 2016-03-17 Janssen Pharmaceutica Nv VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION
CA2970065A1 (en) 2014-12-08 2016-06-16 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
WO2016109427A1 (en) * 2014-12-31 2016-07-07 Icahn School Of Medicine At Mount Sinai Method of maintaining the anti-depressant effect of ketamine with lithium
US9844551B2 (en) 2015-01-14 2017-12-19 Children's Hospital Medical Center Compositions and methods for treatment of fragile X syndrome
WO2016172672A1 (en) * 2015-04-24 2016-10-27 Icahn School Of Medicine At Mount Sinai Method for treating suicidal ideation
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US20160338977A1 (en) * 2015-05-20 2016-11-24 Janssen Pharmaceutica Nv Methods and kits for treating depression
US11191734B2 (en) 2015-06-27 2021-12-07 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
CN106562952B (zh) * 2015-10-09 2020-06-09 江阴安博生物医药有限公司 ***在治疗重性抑郁障碍中的应用
WO2017087691A1 (en) 2015-11-17 2017-05-26 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms
CA3041275A1 (en) * 2016-10-27 2018-05-03 National University Corporation Chiba University Pharmaceutical applications for (s)-norketamine and salts thereof
WO2018234568A2 (en) * 2017-06-23 2018-12-27 Develco Pharma Schweiz Ag HYDROXYNORKETAMINE FOR USE IN TREATING DEPRESSION
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
WO2019094596A1 (en) 2017-11-09 2019-05-16 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
CN107823195A (zh) * 2017-11-24 2018-03-23 无锡市精神卫生中心 R‑***在抑郁症急性期治疗中的应用
CN117531017A (zh) * 2017-12-22 2024-02-09 詹森药业有限公司 用于治疗抑郁症的艾司***
PT3505157T (pt) * 2017-12-29 2022-02-18 Celon Pharma Sa Composição de cetamina em pó seco para administração pulmonar em depressão resistente ao tratamento
WO2019160057A1 (ja) 2018-02-15 2019-08-22 国立大学法人千葉大学 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物
EP3813808A4 (en) 2018-05-04 2022-01-26 Perception Neuroscience, Inc. DRUG TREATMENT METHODS
MX2020012475A (es) * 2018-06-27 2021-04-28 Clexio Biosciences Ltd Metodo para tratar el trastorno depresivo mayor.
WO2020027344A1 (en) * 2018-08-03 2020-02-06 Takeda Pharmaceutical Company Limited Ch24h inhibitors for mdd use
EP3628313A1 (en) 2018-09-28 2020-04-01 Celon Pharma S.A. Ketamine composition for use in a method of treatment of depression by pulmonary administration
CN112702995A (zh) 2018-10-05 2021-04-23 克雷西奥生物科技有限公司 治疗重度抑郁症的艾***的治疗方案
EP3923919A4 (en) * 2019-02-17 2022-12-07 Neurawell Therapeutics COMPOSITIONS AND METHODS FOR THE TREATMENT OF DEPRESSION AND OTHER DISORDERS
WO2020178653A1 (en) 2019-03-05 2020-09-10 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression
CA3140088A1 (en) 2019-05-31 2020-12-03 Celon Pharma S.A. Electronically supervised administration of a pharmaceutical composition
EP3976145A1 (en) 2019-05-31 2022-04-06 Celon Pharma S.A. An inhaler for electronically supervised parenteral administration of a pharmaceutical composition
JP2022546456A (ja) * 2019-08-28 2022-11-04 ヤンセン ファーマシューティカルズ，インコーポレーテッド 自殺傾向を含む大うつ病性障害を有する患者の治療のためのエスケタミン
JP2022548233A (ja) * 2019-09-13 2022-11-17 ヤンセン ファーマシューティカルズ，インコーポレーテッド エスケタミンの鼻腔内投与
WO2021242504A1 (en) * 2020-05-28 2021-12-02 Janssen Pharmaceuticals, Inc. Methods for treating depression
WO2023162987A1 (ja) * 2022-02-22 2023-08-31 国立大学法人京都大学 うつ病および／またはうつ状態の治療および／または予防用医薬

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6176242B1 (en) * 1999-04-30 2001-01-23 Medtronic Inc Method of treating manic depression by brain infusion
EP1103256A1 (de) * 1999-11-26 2001-05-30 Claudius Dr. med. Böck Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom
US7973043B2 (en) * 2002-07-30 2011-07-05 Peter Migaly Combination therapy for depression, prevention of suicide, and various medical and psychiatric conditions
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
JP2009530385A (ja) * 2006-03-22 2009-08-27 マウント シナイ スクール オブ メディシン うつ病の治療のためのケタミンの鼻内投与
RU2008150624A (ru) * 2006-05-22 2010-06-27 Ванда Фармасьютиклз, Инк. (Us) Лечение депрессивных расстройств
DE102007009888A1 (de) * 2007-02-28 2008-09-04 Hermann, Holger Lars, Dr. Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
US20110038807A1 (en) * 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
US8846765B2 (en) * 2010-06-15 2014-09-30 Gruenenthal Gmbh Pharmaceutical combination

Also Published As

Publication number Publication date
GT201400191A (es) 2017-07-03
KR20140136982A (ko) 2014-12-01
CO7071129A2 (es) 2014-09-30
CN104519878A (zh) 2015-04-15
CR20140410A (es) 2014-11-17
HK1209323A1 (en) 2016-04-01
CL2014002406A1 (es) 2015-01-09
WO2013138322A1 (en) 2013-09-19
US20130236573A1 (en) 2013-09-12
MX2014010939A (es) 2014-11-13
PE20141906A1 (es) 2014-12-05
PH12014501997A1 (en) 2014-11-24
SG11201405530SA (en) 2014-11-27
US20140093592A1 (en) 2014-04-03

Similar Documents

Publication Publication Date Title
NI201400104A (es) Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento
BR112016014410A2 (pt) terapia de combinação com vacina de neoantígeno
DOP2014000170A (es) Compuestos de imidazopirrolidinona
UY34984A (es) Métodos para tratar o prevenir asma administrando un antagonista de il-4r.
BR112015026325A2 (pt) dosagem oral de compostos glp-1
CL2014001993A1 (es) Uso de melatonina para el tratamiento de trastornos del ritmo circadiano
CR20140108A (es) Compuesto de ciclopropanoamina
NI201400095A (es) Metodos para el tratamiento del cáncer de pulmon de celulas no pequeñas utilizando terapia combinada de inhibidor tor cinasa.
GT201400166A (es) Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardiaca
NI201200030A (es) Tratamiento anticancerígeno con una combinación de taxanos y 13-dexosiantraciclinas.
NI201400109A (es) Tratamiento del cáncer con inhibidores tor cinasa
BR112013020798A2 (pt) terapia de combinação do inibidor mtor /jak
CL2013003272A1 (es) Métodos de tratamientos terapéuticos contra células b cd19 positivas a través de la administración del inmunoconjugado hub4-dm4 (sar3419); regimenes de administración; artículos manufacturados que contengan el inmunoconjugado
NI201400111A (es) Tratamiento del cáncer con inhibidores tor cinasa
CR20140086A (es) Tratamientos de combinación para hepatitis c
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CR20140400A (es) Terapia combinada para el tratamiento del cancer de ovario
CO7101244A2 (es) Fenilimidazopirazoles sustituidos y su uso
CL2015001610A1 (es) Compuestos derivados de pirimido-[4,5-b]-quinolina-4,5(3h,10h)-dionas para utilizarse como un medicamento para el tratamiento de una enfermedad causada por una mutacion sin sentido; composicion y combinacion farmaceutica que los comprende.
BR112015025719A2 (pt) terapia contra o câncer
CO7160080A2 (es) Composiciones lipídicas de racecadotrillo
ES2569743R1 (es) Uso de la buprenorfina en la fabricación de un medicamento para tratar los efectos secundarios inducidos por opioides
ECSP21015491A (es) Administración prolongada de lasmiditan por la noche para la prevención de la migraña
BR112014011223A8 (pt) Método de tratar uma doença proliferativa
UY31646A1 (es) Uso de fenilimidazolidinas sustituidas para producir medicamentos para el tratamiento del síndrome metabólico